Thursday, June 12, 2014
Jorge G. Guerra, M.D., has joined TrialNetworks as chairman of the advisory board. The TrialNetworks platform, which began as an innovative site engagement and communication portal, has rapidly grown into a comprehensive cloud-based solution for key aspects of a clinical trial from startup through closeout, including feasibility surveys, training, trial conduct efficiency, patient recruitment and retention, site activation and document management.
Avanir Pharmaceuticals and OptiNose have entered into an exclusive North American license agreement for the development and commercialization of OptiNose’s novel Breath Powered intranasal delivery system containing low-dose sumatriptan powder to treat acute migraine. If approved, this product would be the first dry-powder nasal delivery form of sumatriptan.